Opioid addiction claims the life of one American every 19 minutes. A rapidly escalating epidemic, the rise in drug addiction is fueling one of the most pressing health crises of the 21st century, and certainly one of the most complex health problems I’ve seen in my lifetime.
But how do we address the problem? There is much public dialogue and debate surrounding this very question. Solutions are being discussed, changes in policy are being proposed and all the while millions of American lives are hanging in the balance.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker following confirmation of Alex Azar as Secretary of the Department of Health and Human Services (HHS):
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker on the passage of the current continuing resolution, which includes a two-year suspension of the medical device excise tax:
Boston Scientific commends the efforts of key champions in the U.S. House and Senate for their successful efforts to suspend the medical device tax, allowing the device industry to reinvest in work to benefit patients.
LINCOLNSHIRE, ILL. – Nov. 8, 2017 – Sysmex America announced today that its Sysmex XW-100 received clearance from the U.S. Food and Drug Administration (FDA)—making it the first Clinical Laboratory Improvement Amendments (CLIA)-waived, complete blood count (CBC) system. Once prepared for each day’s use, the XW-100 will allow health care professionals to provide patients with blood test results in as few as three minutes.
Royal Philips, a global leader in health technology, today announced the results of a comprehensive, independent, two-year study demonstrating the clinical workflow benefits of its next-generation image-guided therapy platform, Azurion. The study investigated nearly 800 patient procedures to evaluate the impact of Azurion at St. Antonius Hospital in Nieuwegein, the Netherlands. The data demonstrated clinicians' use of Azurion resulted in significant time savings for the hospital, including a 17...
In 1958, Arne Larsson was hospitalized in Sweden with a complete heart block, and his prognosis was bleak. That’s when a team of surgeons, led by Dr. Ake Senning, surgically placed the first implantable pacemaker inside Larsson to increase his heart’s number of beats per minute from 25 to the normal rate of 70. Thanks to technological innovation, the then 43-year-old Larsson lived to be 90 years old.
Since then, several new innovations have come to market, including pacemakers operated by...
MINNETONKA, Minn., Oct. 10, 2017 /PRNewswire/ -- Respicardia, Inc., a private medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) approval of its remedē® System, a transvenous implantable neurostimulation system that stimulates the phrenic nerve, and engages the diaphragm to restore natural breathing during sleep in patients with central sleep apnea (CSA). The regulatory approval was based on findings from the remedē System pivotal trial, which...